simeprevir (olysio) Report issue

Small molecule Approved FDA Fast Track FDA Priority Review FDA
AACT ChEMBL DrugBank Drug Central Drugs@FDA KEGG MeSH PubChem repoDB

Active Ingredient History

NOW
  • Now
Simeprevir is a hepatitis C virus (HCV) NS3/4A protease inhibitor approved for the treatment of Chronic Hepatitis C (genotype 1 and 4). Inhibiting NS3/4A, simeprevir blocks viral replication. In in vitro assays simeprevir was potent against HCV genotype 1a and 1b. Simeprevir must not be administered as monotherapy and should only be prescribed with both peginterferon alfa and ribavirin.   NCATS

Chemistry

  • SMILES: COc1ccc2c(O[C@@H]3C[C@@H]4[C@@H](C3)C(=O)N(C)CCCC\C=C/[C@@H]5C[C@]5(NC4=O)C(=O)NS(=O)(=O)C6CC6)cc(nc2c1C)c7nc(cs7)C(C)C
  • InChIKey: JTZZSQYMACOLNN-VDWJNHBNSA-N
  • Mol. Mass: 749.96
  • ALogP: 5.25
  • ChEMBL Molecules:
    simeprevir  
    simeprevir sodium  
More Chemistry

Pharmacology

Alternative names

olysio | simeprevir | simeprevir sodium | tmc435 | tmc-435 | tmc435350 | tmc-435350

Organizations (44)

Research & Development (44)

Organization Org Type FDA approvals Clinical Trials involvement Org ID Force Sort

Marketing (1)

Organization Org Type FDA approvals Clinical Trials involvement Org ID Force Sort

Indications (24)

Approved Indications (1)


 

Hepatitis C, Chronic

Experimental Indications - Clinical Trial Phases 1-4 (24)


 

Arthritis, Rheumatoid (Phase 1)

Asthma (Phase 1)

Carcinoma, Hepatocellular (Phase 3)

Diarrhea (Phase 1)

Healthy Volunteers (Phase 4)

Hemorrhagic Fever, Ebola (Phase 1/Phase 2)

Hepacivirus (Phase 2)

Hepatitis B, Chronic (Phase 1)

Hepatitis C (Phase 4)

Hepatitis C, Chronic ()

HIV-1 (Phase 1)

HIV Infections (Phase 4)

Hypertension (Phase 1)

Infections (Phase 3)

Infertility, Male (Phase 2/Phase 3)

Kidney Failure, Chronic (Phase 2)

Leukemia, Lymphocytic, Chronic, B-Cell (Phase 1)

Liver Cirrhosis (Phase 4)

Liver Diseases (Phase 2)

Liver Transplantation (Phase 4)

Pharmacokinetics (Phase 1)

Rifampin (Phase 1)

Tuberculosis (Phase 1)

Viruses (Phase 1)

Overview

  • Highest Phase: Phase 4
  • # of Trials: 118
  • # of Trial Organizations: 44

Trials by Phase

Trial Phase Start Date Organizations Indications

Feedback

Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).

Report issue